Skip to main content Skip to navigation
BV421 Mouse Anti-Human CD39
BV421 Mouse Anti-Human CD39
Flow cytometric analysis of CD39 expression on human peripheral blood leucocyte populations. Upper Plots: Whole blood was stained with either BD Horizon™ BV421 Mouse IgG1, κ Isotype Control (Cat No. 562438; Left Plot) or BD Horizon™ BV421 Mouse Anti-Human CD39 antibody (Cat No. 567524/567525; Right Plot). Erythrocytes were lysed with BD FACS™ Lysing Solution (Cat No. 349202). A bivariate pseudocolor density plot showing the correlated expression of CD39 (or Ig Isotype control staining) versus side light-scatter signals (SSC-A) was derived from gated events with the forward and side light-scatter characteristics of intact leucocyte populations. Lower Plots: Human peripheral blood mononuclear cells (PBMC) were preincubated with Human BD Fc Block™ (Cat. No. 564219/564220) and then stained with PE Mouse Anti-Human CD4 (Cat. No. 561844/555347/561843), FITC Mouse Anti-Human CD25 (Cat. No. 555431/560990), BD Horizon™ APC-R700 Mouse Anti-Human CD127 (Cat No. 565185) antibodies, and either BD Horizon™ BV421 Mouse IgG1, κ Isotype Control (dashed line histogram) or BD Horizon™ BV421 Mouse Anti-Human CD39 antibody (solid line histogram). Via-Probe™ Cell Viability 7-AAD Solution (Cat. No. 555815/555816) was added to cells right before analysis. The bivariate pseudocolor density plot showing the coexpressed levels of CD25 versus CD127 by viable (7-AAD-negative) light scatter-gated CD4+ T cells [Left Plot] was further gated to reveal CD39 expression (or Ig Isotype control staining) [Right Plot] on CD4+CD25+CD127low T cells (ie, cells with a Regulatory T cell immunophenotype) as shown. Flow cytometric analysis was performed using a BD LSRFortessa™ X-20 Flow Cytometer System and FlowJo™ software.
Flow cytometric analysis of CD39 expression on human peripheral blood leucocyte populations. Upper Plots: Whole blood was stained with either BD Horizon™ BV421 Mouse IgG1, κ Isotype Control (Cat No. 562438; Left Plot) or BD Horizon™ BV421 Mouse Anti-Human CD39 antibody (Cat No. 567524/567525; Right Plot). Erythrocytes were lysed with BD FACS™ Lysing Solution (Cat No. 349202). A bivariate pseudocolor density plot showing the correlated expression of CD39 (or Ig Isotype control staining) versus side light-scatter signals (SSC-A) was derived from gated events with the forward and side light-scatter characteristics of intact leucocyte populations. Lower Plots: Human peripheral blood mononuclear cells (PBMC) were preincubated with Human BD Fc Block™ (Cat. No. 564219/564220) and then stained with PE Mouse Anti-Human CD4 (Cat. No. 561844/555347/561843), FITC Mouse Anti-Human CD25 (Cat. No. 555431/560990), BD Horizon™ APC-R700 Mouse Anti-Human CD127 (Cat No. 565185) antibodies, and either BD Horizon™ BV421 Mouse IgG1, κ Isotype Control (dashed line histogram) or BD Horizon™ BV421 Mouse Anti-Human CD39 antibody (solid line histogram). Via-Probe™ Cell Viability 7-AAD Solution (Cat. No. 555815/555816) was added to cells right before analysis. The bivariate pseudocolor density plot showing the coexpressed levels of CD25 versus CD127 by viable (7-AAD-negative) light scatter-gated CD4+ T cells [Left Plot] was further gated to reveal CD39 expression (or Ig Isotype control staining) [Right Plot] on CD4+CD25+CD127low T cells (ie, cells with a Regulatory T cell immunophenotype) as shown. Flow cytometric analysis was performed using a BD LSRFortessa™ X-20 Flow Cytometer System and FlowJo™ software.
Product Details
Down Arrow Up Arrow


BD Horizon™
A1; ENTPD1; NTPDase-1; ecto-ATPDase 1; ecto-ATPase 1; ecto-apyrase
Human (QC Testing)
Mouse BALB/c IgG1, κ
PHA-activated Human Peripheral Blood Mononuclear Cells
Flow cytometry (Routinely Tested)
5 µl
V CD39.07; VI CD39,1
Aqueous buffered solution containing BSA and ≤0.09% sodium azide.
RUO


Preparation And Storage

Store undiluted at 4°C and protected from prolonged exposure to light. Do not freeze. The monoclonal antibody was purified from tissue culture supernatant or ascites by affinity chromatography. The antibody was conjugated to the dye under optimum conditions and unconjugated antibody and free dye were removed.

Recommended Assay Procedures

BD® CompBeads can be used as surrogates to assess fluorescence spillover (Compensation). When fluorochrome conjugated antibodies are bound to BD® CompBeads, they have spectral properties very similar to cells.  However, for some fluorochromes there can be small differences in spectral emissions compared to cells, resulting in spillover values that differ when compared to biological controls. It is strongly recommended that when using a reagent for the first time, users compare the spillover on cells and BD® CompBeads to ensure that BD® CompBeads are appropriate for your specific cellular application.

For optimal and reproducible results, BD Horizon Brilliant™ Stain Buffer should be used anytime BD Horizon Brilliant™ dyes are used in a multicolor flow cytometry panel. Fluorescent dye interactions may cause staining artifacts which may affect data interpretation. The BD Horizon Brilliant™ Stain Buffer was designed to minimize these interactions. When BD Horizon Brilliant™ Stain Buffer is used in in the multicolor panel, it should also be used in the corresponding compensation controls for all dyes to achieve the most accurate compensation. For the most accurate compensation, compensation controls created with either cells or beads should be exposed to BD Horizon Brilliant™ Stain Buffer for the same length of time as the corresponding multicolor panel. More information can be found in the Technical Data Sheet of the BD Horizon Brilliant™ Stain Buffer (Cat. No. 563794/566349) or the BD Horizon Brilliant™ Stain Buffer Plus (Cat. No. 566385).

Product Notices

  1. This reagent has been pre-diluted for use at the recommended Volume per Test. We typically use 1 × 10^6 cells in a 100-µl experimental sample (a test).
  2. An isotype control should be used at the same concentration as the antibody of interest.
  3. Source of all serum proteins is from USDA inspected abattoirs located in the United States.
  4. Caution: Sodium azide yields highly toxic hydrazoic acid under acidic conditions. Dilute azide compounds in running water before discarding to avoid accumulation of potentially explosive deposits in plumbing.
  5. Please refer to www.bdbiosciences.com/us/s/resources for technical protocols.
  6. For fluorochrome spectra and suitable instrument settings, please refer to our Multicolor Flow Cytometry web page at www.bdbiosciences.com/colors.
  7. BD Horizon Brilliant Violet 421 is covered by one or more of the following US patents: 8,158,444; 8,362,193; 8,575,303; 8,354,239.
  8. BD Horizon Brilliant Stain Buffer is covered by one or more of the following US patents: 8,110,673; 8,158,444; 8,575,303; 8,354,239.
  9. Please refer to http://regdocs.bd.com to access safety data sheets (SDS).
  10. Pacific Blue™ is a trademark of Life Technologies Corporation.
567525 Rev. 1
Antibody Details
Down Arrow Up Arrow
A1

The A1 monoclonal antibody specifically recognizes human CD39 which is also known as Ecto-ATP diphosphohydrolase 1 (Ecto-ATPase 1 or Ecto-ATPDase 1), Ecto-apyrase or NTPDase 1. CD39 is a ~78 kDa integral membrane glycoprotein that is encoded by ENTPD1 (Ectonucleoside triphosphate diphosphohydrolase 1). CD39 contains two transmembrane domains, one having a N- and the other a C-terminal cytoplasmic tail, and a large extracellular domain that has the enzymatic site. CD39 is also known as Lymphoid cell activation antigen because its expression is induced upon activation of T and B cells. CD39 is variably expressed on some regulatory T cells, NK cells, granulocytes, monocytes, dendritic cells, Langerhans cells, endothelial cells, platelets, and neurons. CD39 is a member of the ectonucleoside triphosphate dihydrolases (E-NTPDases) family that is involved in the regulation of extracellular nucleotide catabolism by controlling the extracellular nucleoside triphosphate pool (NTP). It functions as an ectoenzyme that can hydrolyze both nucleoside triphosphates and diphosphates such as ATP and ADP and thereby suppress inflammation and regulate platelet activation as well as purinergic neurotransmission. The ectoenzymes CD39 and CD73 can act in tandem to enable regulatory T cells (Treg) to generate immunosuppressive adenosine and thereby regulate immune responses.

The antibody was conjugated to BD Horizon™ BV421 which is part of the BD Horizon Brilliant™ Violet family of dyes. With an Ex Max near 407 nm and Em Max near 421 nm, BD Horizon™ BV421 can be excited by the violet laser (405 nm) and detected with a 450/50 nm filter. BD Horizon™ BV421 conjugates are very bright, often exhibiting a 10 fold improvement in brightness compared to Pacific Blue™ conjugates. Due to nearly identical excitation and emission properties but different spillover characteristics, BD Horizon™ BV421, Pacific Blue™, and BD Horizon™ V450 cannot be used simultaneously.

567525 Rev. 1
Format Details
Down Arrow Up Arrow
BV421
The BD Horizon Brilliant Violet™ 421 (BV421) Dye is part of the BD Horizon Brilliant Violet™ family of dyes. This polymer-technology based dye has an excitation maximum (Ex Max) of 407-nm and an emission maximum (Em Max) at 423-nm. Driven by BD innovation, BV421 is designed to be excited by the violet laser (405-nm) and detected using an optical filter centered near 420-nm (e.g., a 431/28-nm or 450/50-nm bandpass filter). BV421 is an ideal alternative for V450 as it is approximately ten times brighter with less spillover into the BV510/V500 detector. Please ensure that your instrument’s configurations (lasers and optical filters) are appropriate for this dye.
altImg
BV421
Violet 405 nm
407 nm
423 nm
567525 Rev.1
Citations & References
Down Arrow Up Arrow
View product citations for antibody "567525" on CiteAb

Development References (6)

  1. Allard B, Longhi MS, Robson SC, Stagg J. The ectonucleotidases CD39 and CD73: Novel checkpoint inhibitor targets.. Immunol Rev. 2017; 276(1):121-144. (Biology). View Reference
  2. Aversa GG, Suranyi MG, Waugh JA, Bishop AG, Hall BM. Detection of a late lymphocyte activation marker by A1, a new monoclonal antibody.. Transplant Proc. 1988; 20(1):49-52. (Immunogen: Flow cytometry). View Reference
  3. Aversa GG, Waugh JA, Bishop GA, Hall BM. Use of monoclonal antibodies to study in vivo and in vitro-activated lymphocytes.. Transplant Proc. 1989; 21(1 Pt 1):349-50. (Clone-specific: Flow cytometry). View Reference
  4. Gouttefangeas C, Mansur I, Bensussan A, Boumsell L. Biochemical analysis and epitope mapping of mAb defining CD39. In: Schlossman SF. Stuart F. Schlossman .. et al., ed. Leucocyte typing V : white cell differentiation antigens : proceedings of the fifth international workshop and conference held in Boston, USA, 3-7 November, 1993. Oxford: Oxford University Press; 1995:383-385.
  5. Häusler SF, Del Barrio IM, Diessner J, et al. Anti-CD39 and anti-CD73 antibodies A1 and 7G2 improve targeted therapy in ovarian cancer by blocking adenosine-dependent immune evasion.. Am J Transl Res. 2014; 6(2):129-39. (Clone-specific: Flow cytometry, Functional assay, Inhibition). View Reference
  6. Jones M, Mason DY. CD39 Workshop Panel report. In: Kishimoto T. Tadamitsu Kishimoto .. et al., ed. Leucocyte typing VI : white cell differentiation antigens : proceedings of the sixth international workshop and conference held in Kobe, Japan, 10-14 November 1996. New York: Garland Pub.; 1997:157-159.
View All (6) View Less
567525 Rev. 1

 

Please refer to Support Documents for Quality Certificates


Global - Refer to manufacturer's instructions for use and related User Manuals and Technical data sheets before using this products as described


Comparisons, where applicable, are made against older BD Technology, manual methods or are general performance claims.  Comparisons are not made against non-BD technologies, unless otherwise noted.

For Research Use Only. Not for use in diagnostic or therapeutic procedures.